This article is more than 5 years old. Information may no longer be current.

QLT signs research collaboration, option agreement with Wilmer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER — QLT has entered into a 2-year, $1.45 million collaboration agreement with Johns Hopkins University's Wilmer Eye Institute to research and develop treatments for nonexudative age-related macular degeneration, the company announced.

The agreement provides QLT with the first option to negotiate an exclusive license to patented products stemming from research conducted at the center with its funding. Should QLT choose to license a product, the company will pay Johns Hopkins financial milestones and royalties, according to a press release from QLT.